MBLi program

Novel and potent metallo ß-lactamase (MBL) inhibitor (ANT2681) to be combined with meropenem for the treatment of MBL-producing carbapenem-resistant Enterobacterales (CRE), particularly NDM carrying strains, which are prevalent throughout China and the Asia Pacific region and for which no inhibitors are currently available. ANT2681 has recently received QIDP status from the FDA for complicated Urinary Tract Infection (cUTI) and is ready for progression to Phase I.